Search Results - "BRAIMAN, J"

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis by Miller, R G, Moore, D, Young, L A, Armon, C, Barohn, R J, Bromberg, M B, Bryan, W W, Gelinas, D F, Mendoza, M C, Neville, H E, Parry, G J, Petajan, J H, Ravits, J M, Ringel, S P, Ross, M A

“…We designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with amyotrophic lateral…”
Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

“…Background and objective: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a…”
Get full text

United States Vaccine Research: A Delicate Fabric of Public and Private Collaboration by Committee, National Vaccine Advisory

“…In the last 20 years, two thirds of all new vaccines provided worldwide have been produced by a US network of independent industrial, governmental, and…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis: Multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997 by Rudick, R A, Goodkin, D E, Jacobs, L D, Cookfair, D L, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Granger, C V, Simon, J H, Alam, J J, Simonian, N A, Campion, M K, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, F E, Priore, R L, Pullicino, P M, Scherokman, B J, Weistock-Guttman, B, Whitham, R H

Get full text

Continuous involuntary auricular movements associated with an anterior parietal tumor by Jabbari, B, Braiman, J

Get more information

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group by Rudick, R A, Cookfair, D L, Simonian, N A, Ransohoff, R M, Richert, J R, Jacobs, L D, Herndon, R M, Salazar, A M, Fischer, J S, Granger, C V, Goodkin, D E, Simon, J H, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munchsauer, F E, O'Reilly, K, Priore, R L, Whitham, R H

“…This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III…”
Get full text

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group by Simon, J H, Jacobs, L D, Campion, M, Wende, K, Simonian, N, Cookfair, D L, Rudick, R A, Herndon, R M, Richert, J R, Salazar, A M, Alam, J J, Fischer, J S, Goodkin, D E, Granger, C V, Lajaunie, M, Martens-Davidson, A L, Meyer, M, Sheeder, J, Choi, K, Scherzinger, A L, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Whitham, R H

“…The Multiple Sclerosis Collaborative Research Group trial was a double-blind, randomized, multicenter, phase III, placebo-controlled study of interferon…”
Get more information

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Goodkin, D E, Priore, R L, Wende, K E, Campion, M, Bourdette, D N, Herndon, R M, Fischer, J S, Jacobs, L D, Cookfair, D L, Rudick, R A, Richert, J R, Salazar, A M, Granger, C V, Simon, J H, Alam, J J, Bartoszak, D M, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, 3rd, F E, Whitham, R H

“…We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25…”
Get more information

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Rudick, R A, Goodkin, D E, Jacobs, L D, Cookfair, D L, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Granger, C V, Simon, J H, Alam, J J, Simonian, N A, Campion, M K, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, F E, Priore, R L, Whitham, R H

“…A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed…”
Get full text

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) by Jacobs, L D, Cookfair, D L, Rudick, R A, Herndon, R M, Richert, J R, Salazar, A M, Fischer, J S, Goodkin, D E, Granger, C V, Simon, J H, Alam, J J, Bartoszak, D M, Bourdette, D N, Braiman, J, Brownscheidle, C M, Coats, M E, Cohan, S L, Dougherty, D S, Kinkel, R P, Mass, M K, Munschauer, 3rd, F E, Priore, R L, Pullicino, P M, Scherokman, B J, Whitham, R H

“…The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations…”
Get more information

Enkephalin fibers in autonomic nuclear regions: intraspinal vs. supraspinal origin by Romagnano, M A, Braiman, J, Loomis, M, Hamill, R W

“…The present studies in the rat employ spinal transections and hemisections, dorsal and/or ventral rhizotomies to determine whether enkephalin fibers in spinal…”
Get more information